// App-Quantinova.ai

TCT-32 : Prospective, Multi-Center Evaluation of the DESolve Novolimus-Eluting Bioresorbable Coronary Scaffold: Imaging Outcomes and 4-Year Clinical and Imaging Results

Researchers

Presenter

  • Stefan Verheye

Principal Investigators

  • Lynn Morrison

  • Joachim Schofer

  • Juliana Castro

  • Michael Maeng

  • Rajiv Jauhar

  • Carsten Skurk

  • Roberto Botelho

  • John Ormiston

  • Ricardo Costa

  • Jose Costa Jr

  • Daniel Chamie

Medical Centers

  • Triangulo Heart Institute, Uberlandia, Brazil

  • Zealand University Hospital, Aarhus N, Denmark

  • Cardiovascular Institute Middelheim, Antwerp, Belgium

  • Auckland City Hospital, Auckland, New Zealand

  • Elixir Medical, sunnyvale, California, United States

  • Hamburg University Cardiovascular Center and Department for percutaneous treatment of structural hea, Hamburg, Germany

  • ICU, Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil

  • de Sao Paulo, Sao Paulo, Brazil

  • Charite Berlin, Berlin, Germany

Locations

  • Brazil

  • Germany

  • United States

  • Denmark

  • Belgium

  • New Zealand

Companies

  • Elixir medical corpo

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Coronary artery lesions

  • Venous thrombosis

Biomarkers

  • Serine/threonine-protein kinase mTOR

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved